Strem Brian M.'s Form 4 filing
Kiora Pharmaceuticals Inc (KPRX) · filed Nov 22, 2021
- Accession no.
- 0001104659-21-142537
- Filed
- Nov 22, 2021
- Trade date
- Oct 21-Nov 18, 2021
- Filing delay
- 32 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market purchases total $25.2K. It was filed 32 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Strem Brian M.CIK 0001876429 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Received by the Reporting Person in connection with the acquisition by the issuer of all of the outstanding securities of Bayon Therapeutics, Inc. on October 21, 2021.
Referenced by the price of 1 transaction in Table I.
- F2
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.395 to $1.41, inclusive. The reporting person hereby undertakes to provide to Kiora Pharmaceuticals, Inc., any security holder of Kiora Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.
Referenced by the price of 1 transaction in Table I.